|
US5175320A
(en)
|
1989-04-17 |
1992-12-29 |
Giuliani S.P.A. |
Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
|
|
ES2306459T3
(es)
|
1996-05-23 |
2008-11-01 |
Novartis Ag |
Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca).
|
|
AU2002308295B2
(en)
|
2001-03-12 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Steroids as agonists for FXR
|
|
WO2003039480A2
(en)
|
2001-11-08 |
2003-05-15 |
The University Of Chicago |
Method of treating disorder related to high cholesterol concentration
|
|
EP1568706A1
(en)
|
2004-02-26 |
2005-08-31 |
Intercept Pharmaceuticals, Inc. |
Novel steroid agonist for FXR
|
|
EP3175855B1
(en)
|
2004-03-12 |
2020-07-15 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using fxr ligands
|
|
CA2561264A1
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
JP2010517931A
(ja)
|
2006-02-14 |
2010-05-27 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
|
|
PL2040713T3
(pl)
|
2006-06-27 |
2014-11-28 |
Intercept Pharmaceuticals Inc |
Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
|
|
AU2008209566C1
(en)
|
2007-01-19 |
2013-02-14 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as TGR5 modulators and methods of use thereof
|
|
AU2009276507B2
(en)
|
2008-07-30 |
2015-11-19 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
JP5639073B2
(ja)
|
2008-11-19 |
2014-12-10 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｔｇｒ５モジュレーターおよびその使用方法
|
|
CA2744189C
(en)
|
2008-11-19 |
2016-10-11 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
SG10201607230SA
(en)
|
2012-06-19 |
2016-10-28 |
Intercept Pharmaceuticals Inc |
Preparation, Uses And Solid Forms Of Obeticholic Acid
|
|
SMT201700602T1
(it)
|
2012-10-26 |
2018-03-08 |
Intercept Pharmaceuticals Inc |
Processo per la preparazione di derivati dell’acido biliare
|
|
US20140206657A1
(en)
|
2013-01-18 |
2014-07-24 |
City Of Hope |
Bile acid analog tgr5 agonists
|
|
EP3865135A3
(en)
|
2013-03-13 |
2021-11-03 |
Sage Therapeutics, Inc. |
Neuroactive steroids for use in therapy
|
|
PT3360882T
(pt)
|
2013-05-14 |
2021-02-12 |
Intercept Pharmaceuticals Inc |
Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x
|
|
CN104938001B
(zh)
|
2013-12-10 |
2019-04-12 |
华为终端有限公司 |
一种注册方法和相关节点以及注册系统
|
|
HK1243930A1
(zh)
*
|
2014-11-06 |
2018-07-27 |
英安塔制药有限公司 |
作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
|
|
MX381239B
(es)
|
2014-11-19 |
2025-03-12 |
Nzp Uk Ltd |
Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
|
|
PL3221333T3
(pl)
|
2014-11-19 |
2020-01-31 |
NZP UK Limited |
Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
|
|
EP3221332B1
(en)
|
2014-11-19 |
2019-04-24 |
NZP UK Limited |
5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
SG11201703997XA
(en)
*
|
2014-11-26 |
2017-06-29 |
Enanta Pharm Inc |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
WO2016086134A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
CN105348365A
(zh)
|
2014-12-03 |
2016-02-24 |
四川百利药业有限责任公司 |
一种胆酸衍生物及其制备方法、药物组合物和用途
|
|
TN2017000344A1
(en)
|
2015-02-06 |
2019-01-16 |
Intercept Pharmaceuticals Inc |
Pharmaceutical compositions for combination therapy
|
|
JP2018505190A
(ja)
|
2015-02-11 |
2018-02-22 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
|
|
SG11201707328SA
(en)
|
2015-03-09 |
2017-10-30 |
Intercept Pharmaceuticals Inc |
Methods for modulating bone density
|
|
CN107531741A
(zh)
|
2015-03-10 |
2018-01-02 |
美莱斯股份有限公司 |
氟化和烷基化胆酸
|
|
US20160279393A1
(en)
|
2015-03-25 |
2016-09-29 |
Covidien Lp |
Guidewire retrieval catheter
|
|
RS62110B1
(sr)
|
2015-03-31 |
2021-08-31 |
Enanta Pharm Inc |
Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
|
|
SMT202400104T1
(it)
|
2015-04-07 |
2024-05-14 |
Intercept Pharmaceuticals Inc |
Composizioni farmaceutiche per politerapia
|
|
PE20180690A1
(es)
|
2015-04-27 |
2018-04-23 |
Intercept Pharmaceuticals Inc |
Composiciones de acido obeticolico y metodos de uso
|
|
WO2016173493A1
(en)
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
WO2016173397A1
(zh)
|
2015-04-28 |
2016-11-03 |
上海翰森生物医药科技有限公司 |
胆酸衍生物及其制备方法和医药用途
|
|
TW201704251A
(zh)
|
2015-04-29 |
2017-02-01 |
正大天晴藥業集團股份有限公司 |
鵝去氧膽酸衍生物
|
|
CN106210599B
(zh)
|
2015-04-30 |
2021-02-12 |
中兴通讯股份有限公司 |
一种多画面调整方法、装置及多点控制单元
|
|
AU2016280806B2
(en)
|
2015-06-19 |
2021-01-28 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
NZ739219A
(en)
|
2015-07-30 |
2019-03-29 |
Intercept Pharmaceuticals Inc |
Methods for preparation of bile acids and derivatives thereof
|
|
BR112018002499A2
(pt)
|
2015-08-07 |
2018-09-18 |
Intercept Pharmaceuticals Inc |
método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
|
|
CN106518946A
(zh)
*
|
2015-09-10 |
2017-03-22 |
上海迪诺医药科技有限公司 |
磺酰脲衍生物、其药物组合物及应用
|
|
EP3352768B1
(en)
|
2015-09-21 |
2022-11-02 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
EP3353189A4
(en)
|
2015-09-24 |
2019-06-19 |
Intercept Pharmaceuticals, Inc. |
METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
|
|
KR20180061351A
(ko)
|
2015-10-07 |
2018-06-07 |
인터셉트 파마슈티컬즈, 인크. |
파네소이드 x 수용체 조절제
|
|
CN108348533A
(zh)
|
2015-11-06 |
2018-07-31 |
英特塞普特医药品公司 |
制备奥贝胆酸及其衍生物的方法
|
|
WO2017111979A1
(en)
|
2015-12-22 |
2017-06-29 |
Intercept Pharmaceuticals, Inc. |
Polymorphic crystalline forms of obeticholic acid
|
|
CN105646634A
(zh)
|
2016-01-29 |
2016-06-08 |
中国药科大学 |
奥贝胆酸杂质的制备方法
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
JP6892457B2
(ja)
|
2016-03-11 |
2021-06-23 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
３−デスオキシ誘導体およびその医薬組成物
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
GB201608779D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|